These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8748333)

  • 1. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice.
    Srinivas NR; Shyu WC; Weiner RS; Tay LK; Greene DS; Barbhaiya RH
    J Pharm Sci; 1995 Dec; 84(12):1488-9. PubMed ID: 8748333
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.
    Srinivas NR; Shyu WC; Weiner RS; Warner G; Comereski C; Tay LK; Greene DS; Barbhaiya RH
    Pharm Res; 1997 Jul; 14(7):911-6. PubMed ID: 9244149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat.
    Perico N; Amuchastegui S; Bontempelli M; Remuzzi G
    Transplantation; 1996 May; 61(9):1320-2. PubMed ID: 8629290
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses.
    Srinivas NR; Weiner RS; Warner G; Shyu WC; Davidson T; Fadrowski CG; Tay LK; Lee JS; Greene DS; Barbhaiya RH
    J Pharm Sci; 1996 Jan; 85(1):1-4. PubMed ID: 8926572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
    Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
    J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice.
    Srinivas NR; Weiner RS; Shyu WC; Calore JD; Tritschler D; Tay LK; Lee JS; Greene DS; Barbhaiya RH
    J Pharm Sci; 1996 Mar; 85(3):296-8. PubMed ID: 8699332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.
    Tivol EA; Boyd SD; McKeon S; Borriello F; Nickerson P; Strom TB; Sharpe AH
    J Immunol; 1997 Jun; 158(11):5091-4. PubMed ID: 9164923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo mechanism of action of CTLA4Ig.
    Judge TA; Tang A; Spain LM; Deans-Gratiot J; Sayegh MH; Turka LA
    J Immunol; 1996 Mar; 156(6):2294-9. PubMed ID: 8690920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
    Bolling SF; Lin H; Wei RQ; Turka LA
    J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression.
    Guillot C; Mathieu P; Coathalem H; Le Mauff B; Castro MG; Tesson L; Usal C; Laumonier T; Brouard S; Soulillou JP; Lowenstein PR; Cuturi MC; Anegon I
    J Immunol; 2000 May; 164(10):5258-68. PubMed ID: 10799887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4Ig-induced linked regulation of allogeneic T cell responses.
    Lee RS; Rusche JR; Maloney ME; Sachs DH; Sayegh MH; Madsen JC
    Transplant Proc; 2001; 33(1-2):88-9. PubMed ID: 11266718
    [No Abstract]   [Full Text] [Related]  

  • 12. A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection.
    Weiner RS; Srinivas NR; Calore JD; Fadrowski CG; Shyu WC; Tay LK
    J Pharm Biomed Anal; 1997 Feb; 15(5):571-9. PubMed ID: 9127268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nippostrongylus brasiliensis can induce B7-independent antigen-specific development of IL-4-producing T cells from naive CD4 T cells in vivo.
    Liu Z; Liu Q; Pesce J; Whitmire J; Ekkens MJ; Foster A; VanNoy J; Sharpe AH; Urban JF; Gause WC
    J Immunol; 2002 Dec; 169(12):6959-68. PubMed ID: 12471130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.
    Daikh DI; Wofsy D
    J Immunol; 2001 Mar; 166(5):2913-6. PubMed ID: 11207238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7 requirements for primary and secondary protein- and polysaccharide-specific Ig isotype responses to Streptococcus pneumoniae.
    Wu ZQ; Khan AQ; Shen Y; Schartman J; Peach R; Lees A; Mond JJ; Gause WC; Snapper CM
    J Immunol; 2000 Dec; 165(12):6840-8. PubMed ID: 11120807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preoperative inoculation of CTLA4Ig combined with allogeneic dendritic cells prolongs rat renal allograft survival in a donor-specific fashion].
    Harada H
    Hokkaido Igaku Zasshi; 1999 May; 74(3):189-98. PubMed ID: 10422563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA4IgG in a murine model of type II collagen-induced arthritis.
    Ijima K; Murakami M; Okamoto H; Inobe M; Chikuma S; Saito I; Kanegae Y; Kawaguchi Y; Kitabatake A; Uede T
    Hum Gene Ther; 2001 Jun; 12(9):1063-77. PubMed ID: 11399228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-13-mediated worm expulsion is B7 independent and IFN-gamma sensitive.
    Urban J; Fang H; Liu Q; Ekkens MJ; Chen SJ; Nguyen D; Mitro V; Donaldson DD; Byrd C; Peach R; Morris SC; Finkelman FD; Schopf L; Gause WC
    J Immunol; 2000 Apr; 164(8):4250-6. PubMed ID: 10754322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.
    Kay MA; Meuse L; Gown AM; Linsley P; Hollenbaugh D; Aruffo A; Ochs HD; Wilson CB
    Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4686-91. PubMed ID: 9114052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.
    Linsley PS; Wallace PM; Johnson J; Gibson MG; Greene JL; Ledbetter JA; Singh C; Tepper MA
    Science; 1992 Aug; 257(5071):792-5. PubMed ID: 1496399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.